Skip to main content

Month: February 2016

Incorporating In Vitro Information on Drug Metabolism into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphisms on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application

By

In vitro-in vivo extrapolation of clearance, embedded in a clinical trial simulation, was used to investigate differences in the pharmacokinetics and pharmacodynamics of dextromethorphan between CYP2D6 poor and extensive metabolizer phenotypes. Information on the genetic variation of CYP2D6, as well as the in vitro metabolism and pharmacodynamics of dextromethorphan and its active metabolite dextrorphan, was … Continued

2 of 2